

12 - 13 - 05


JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/616,692
Applicant : Nelson, Jodi
Filed : July 9, 2003
TC/A.U. : 1614
Examiner : Unassigned
For : Compositions and Methods
For the Treatment of
Parkinson's Disease and
Tardive Dyskinesias

Docket No. : 47-00B
Customer No.: 23713

Confirmation No. 1639

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for Express Mail in an envelope addressed to:	
Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450	
December 12, 2005 Date	 Ronald Friedland
EV 693371921 US Express Mail Tracking Number	

Hon. Commissioner for Patents
Mail Stop Amendment
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Further to the Information Disclosure Statements filed August 24, 2005, June 10, 2005, June 27, 2005, and September 20, 2005, the Examiner is respectfully requested to consider the additional references, copies enclosed, which may qualify as prior art. For the Examiner's convenience, the references are listed on the attached Patent and Trademark Office Form PTO-1449.

References known to the applicants have been listed on the enclosed form PTO-1449 or a substitute. That information is cited in a spirit of forthrightness and cooperation to enable the applicants to obtain that measure of protection for the invention to which there is entitlement. However, no representation is made that the listed art actually qualifies as prior art under the patent statute and the mere use of form

PTO-1449 or a substitute is not an admission that all listed references are prior art. No representation is made that applicants know of the best art.

It is believed this submission does not require the payment of any fees; however, if this is incorrect, please credit any overpayment or deduct any additional fees due from deposit account no. 07-1969, including fees for additional extensions of time which may be required.

Respectfully submitted,



Ellen P. Winner
Reg. No. 28,547

GREENLEE, WINNER AND SULLIVAN, P.C.
4875 Pearl East Circle, Suite 200
Boulder, CO 80301
Telephone: (303) 499-8080
Facsimile: (303) 499-8089
E-mail: winner@greenwin.com
Attorney docket No. 47-00B
December 12, 2005

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/616,692
Filing Date	09/07/2003
First Named Inventor	Nelson
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	47-00B

GWS 12/12/2005

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)
	1	5,496,836	03/05/1996	Di Rocco et al.	
	2	5,352,688	10/04/1994	Kaminski	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	ABIOSE, A.K., et al., Chloroquine-induced venodilation in human hand veins; <i>Clinical Pharmacology & Therapeutics</i> , June 1997, Vol. 61, No. 6, 677-683.	
	4	ADLER, L.E., et al., Cimetidine Toxicity Manifested as Paranoia and Hallucinations; <i>Am J Psychiatry</i> , Sept. 1980, 137:9, 1112-1113.	
	5	BATEMAN, D. N., et al., Cimetidine induced postural and action tremor; <i>J Neurol Neurosurg Psychiatry</i> , Jan. 1981, 44(1):94.	
	6	AMABEOKU, G. J., Some behavioural effects of chloroquine in rats suggesting dopaminergic activation; <i>Indian J Med Res.</i> , Feb. 1994, 99:87-94.	
	7	BYRON, J. W., Mechanism for Histamine H ₂ -Receptor Induced Cell-Cycle Changes in the Bone Marrow Stem Cell; <i>Agents & Actions</i> , Jul. 1977, 7(2):209-13.	
	8	DONATELLI, P., et al., Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain; <i>Eur J Clin Pharmacol.</i> , 1994, 47(4):345-9, abstract only.	
	9	ETTE, E.I., et al., Effect of ranitidine on chloroquine disposition; <i>Drug Intell Clin Pharm.</i> , Sept. 1987, 21(9):732-4.	
	10	GARCIA-RUIZ, P.J., et al., Cinnarizine-induced parkinsonism in primates; <i>Clinical Neuropharmacology</i> , Apr 1992, 15(2):152-4, abstract only.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Substitute for form 1449/PTO, based on PTO/SB/08A and 08B	Application Number	10/616,692
		Filing Date	09/07/2003
		First Named Inventor	Nelson
		Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	47-00B

GWS 12/12/2005


Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	GARCIA-RUIZ, P.J., et al., Parkinsonism associated with calcium channel blockers: a prospective follow-up study, <i>Clinical Neuropharmacology</i> , Feb. 1992, 15(1):19-26, abstract only.	
	12	HANDLER, C. E., et al., Extrapyramidal and cerebellar syndrome with encephalopathy associated with cimetidine; <i>Postgrad Med Journal</i> , Aug. 1982, 58:527-528.	
	13	HARLE, D.G., et al., Structural features of potent inhibitors of rat kidney histamine N-methyltransferase; <i>Biochem Pharmacol.</i> , Feb. 1988, 37(3):385-8, abstract only.	
	14	HUTCHISON, T. A., et al., Comparative Dosage Table – Histamine H2 Receptors; <i>Drugdex® System</i> , 2000.	
	15	KUSHNER, M. J., Chorea and Cimetidine; <i>Annals of Internal Medicine</i> , Jan. 1982, 96(1):126.	
	16	KUZUHARA, S., et al., Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade – report of 31 cases; <i>Shinkeigaku (Japan)</i> , June 1989, 29(6):681-6, abstract only.	
	17	LEHMANN, A. B., Reversible Chorea Due to Ranitidine and Cimetidine; <i>The Lancet</i> , July 1988, 2(8603):158.	
	18	LOT, T. Y., The effects of chronic administration of chloroquine and quinacrine on the response of normal and denervated smooth muscle to agonist drugs; <i>Physiol Behav.</i> , Aug. 1993, 54(2):345-9, abstract only.	
	19	McMAHON, T., Dyskinesia associated with amoxapine withdrawal and use of carbamazepine and antihistamines; <i>Psychosomatics</i> , Feb. 1986, 27(2):145-148.	
	20	NEGROTTI, A., et al., Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility, <i>Neurotoxicology</i> , Spring 1992, 13(1):261-264, abstract only.	
	21	POIRIER, J., et al., Debrisoquine Metabolism in Parkinsonian Patients Treated with Antihistamine Drugs, <i>The Lancet</i> , Aug. 1987, p. 386.	
	22	PORTER, J. B., et al., Intensive Hospital Monitoring Study of Intravenous Cimetidine, <i>Arch Intern Med</i> , Nov. 1986, 146:2237-9.	
	23	TAKAHASHI, A., et al., Drug-induced movement disorders; <i>Nippon rinsho (Japan)</i> , Nov. 1993, 51(11):2929-34, abstract only.	
	24	TOTTE, J., et al., Neurological Dysfunction Associated with Abnormal Levels of Cimetidine Metabolite, <i>The Lancet</i> , May 1981, 1(8228):1047.	
	25	Micro Medex website, DRUGDEX® Drug Point, Drug Point® Summary, FAMOTIDINE, printout Dec. 2005	
	26	Micro Medex website, CIME Adult Dosages, printout Dec. 2005	
	27	Micro Medex website, CQ Precautions, printout Dec. 2005	
	28	Micro Medex website, CIME – Neurological AEs, printout Dec. 2005	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.



CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Attorney Docket No.:47-00B

Applicant(s): Nelson
Serial No.: 10/616,692
Filing Date: 07/09/2003
Title: **Composites and Methods for the Treatment of
Parkinson's Disease and Tardive Dyskinesias**

I hereby certify that the following correspondence, along with any other document referenced to as being attached or enclosed:

1. **Substitute for PTO Form 1449 – 2 pages**
2. **Supplemental Information Disclosure Statement – 2 pages**
3. **Copy of 28 references**
4. **Certificate of Mailing by Express Mail (37 CFR 1.10) – 1 page**
5. **Return Postcard**

Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents,
PO Box 1450
Alexandria, VA 22313-1450

On December 12, 2005

Ronald Friedland

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

EV693371921US

("Express Mail" Mailing Label Number)